FDA peptide vote explained: Why these drugs are not approved yet

US-Iran warTrump tariffsRussia Ukraine strikesBankipur bypoll election result First AI HomeLive TVFirst AI Sections WorldEntertainmentExplainersCricketSportsOpinionIndiaTechAutoLifestyleHealthBusinessVideosImpact ShortsWeb Stories Shows Van

US-Iran warTrump tariffsRussia Ukraine strikesBankipur bypoll election result First AI HomeLive TVFirst AI

Sections

WorldEntertainmentExplainersCricketSportsOpinionIndiaTechAutoLifestyleHealthBusinessVideosImpact ShortsWeb Stories Shows

VantageFirstpost AmericaFirstpost AfricaFirst SportsSpotlightLive TV Events

FIFA World CupUnion BudgetIndependence DayDelhi Elections 2025 FDA peptide vote explained: Why these drugs are not approved yet A recent FDA advisory panel vote on controversial peptides has sparked confusion, with many believing they are now approved.

Experts clarify what the decision actually means and why these compounds remain unproven Are peptides now FDA-approved?

Experts explain the recent FDA advisory panel vote, what it means for patients, and the risks of unproven peptide therapies.

PixabayToufiq Rashid|Aug 04, 2026, 14:02:27 IST For years, some peptides have been promoted as the next frontier in anti-ageing, sports recovery and longevity.

Celebrities, athletes and wellness influencers have promoted them.

Yet regulators have repeatedly warned that many of these products, available mostly in the grey market, lack evidence and clinical proof and may carry unknown risks.

A recent vote by a US Food and Drug Administration FDA advisory committee has now reignited the debate, with headlines suggesting that several of these controversial peptides have been “approved”.

But that is not what happened.

Six of these compounds cleared a major hurdle last week, when the advisory panel voted in favour of making them available through compounding pharmacies, specialised medical stores that create customised medications, mix individual ingredients, and change drug forms for patients.

Unlike large pharmaceutical companies, these compounding pharmacies make ingredients from scratch to suit patients' individual needs.

However, the FDA has not said that these peptides have been shown to be safe and effective, nor does it amount to FDA approval for treating diseases.

“The current peptide controversy is about several experimental peptides that are promoted for muscle recovery, anti-ageing, inflammation and brain health, but have very limited evidence from human clinical trials.

None of these are approved for clinical use,” says Dr Anoop Misra, Executive Chairman of Fortis C-DOC Hospital for Diabetes and Allied Sciences.

Peptides are short chains of amino acids, the building blocks of proteins.

While proteins may contain hundreds or thousands of amino acids, peptides are much smaller, usually comprising between two and 50 amino acids.

Many peptides occur naturally in the human body, where they act as hormones or signalling molecules, helping regulate appetite, metabolism, growth, immunity and tissue repair.

Scientists have learned to synthesise these molecules, giving rise to a growing class of peptide-based medicines.

Some peptide drugs have transformed modern medicine.

Diabetes and obesity drugs such as Ozempic semaglutide , Wegovy semaglutide , Mounjaro tirzepatide , Zepbound tirzepatide , Victoza liraglutide and Saxenda liraglutide are all peptide medicines that have undergone thorough clinical trials and received FDA approval for specific medical conditions.

However, another category of peptides has exploded in popularity through wellness clinics and online sellers.

These products are marketed for muscle growth, injury healing, anti-ageing, cognitive enhancement and longevity despite limited or incomplete human evidence.

“Peptides are not one uniform class of miracle medicines.

Some peptide drugs, such as insulin and approved GLP-1 therapies, are supported by extensive clinical trials and regulated manufacturing.

The current controversy concerns a different group of experimental peptides being marketed with very limited human evidence,” said Dr Aijaz Ilmi, Senior Consultant, Pacific OneHealth Hospital.

The FDA advisory committee recently voted to recommend that six peptides be considered for inclusion on the list of bulk drug substances that may be used by compounding pharmacies under Section 503A of the US Federal Food, Drug and Cosmetic Act.

Used or studied in some countries, but lacks the evidence required for US drug approval Sleep and “anti-ageing”, because of proposed effects on telomeres and cellular ageing, although convincing human evidence is lacking Unlike Ozempic or Wegovy, none of these peptides has completed the full FDA drug approval process.

Interest in peptides has surged globally with the growth of wellness and longevity clinics.

Social media influencers, biohackers, professional athletes and anti-ageing clinics frequently promote peptide injections for: Many users describe dramatic benefits, but most claims are based on anecdotes with no backing from large, well-controlled clinical trials.

The problem is the purchase of unapproved peptide products sold online.

The agency highlights a lack of adequate human safety studies, unknown long-term side effects, inconsistent manufacturing quality, and the risk of contaminants in compounded or illegally marketed products.

Some products sold as research chemicals have also been found to contain incorrect doses or substances different from those listed on the label.

The recent vote has generated confusion because many reports incorrectly described it as FDA approval.

Instead, the FDA’s Pharmacy Compounding Advisory Committee PCAC recommended that these peptides be considered for inclusion on the 503A Bulks List.

If the FDA ultimately accepts the recommendation, licensed compounding pharmacies may be permitted to prepare medicines using these peptide ingredients when legally appropriate and when patients have a genuine medical need.

The committee’s recommendation is advisory, not binding.

The FDA will review the evidence before making a final decision.

“The recent FDA advisory committee vote should not be described as FDA approval.

The committee only recommended that certain peptides may be considered for preparation by licensed compounding pharmacies.

The FDA must still decide whether and how to act on that recommendation,” said Dr Ilmi.

Even if compounding is permitted, the resulting products, he says, will remain unapproved medicines.

“Their safety, effectiveness, dose consistency, and manufacturing quality will not have been evaluated in the same manner as an FDA-approved drug.

There is a legitimate argument that regulated pharmacy compounding may be safer than patients buying injectable peptides from anonymous online sellers.

But improved access cannot replace proper clinical trials.

We must separate biological promise from proven clinical benefit,” he added.

The peptides remain unapproved drugs.

Doctors cannot suddenly prescribe them as FDA-approved treatments for injuries, ageing or chronic diseases.

“The responsible position is neither to dismiss all peptide science nor to promote these products as rejuvenation shortcuts.

Each peptide must be evaluated individually by transparent human studies, standardised manufacturing, adverse-event monitoring and clearly defined indications,” Dr Ilmi explains.

“Until then, patients should understand that ‘available through a pharmacy’, ‘recommended by an advisory panel’ and ‘FDA-approved’ are three very different things.

The FDA advisory panel may have provided an opportunity for regulated compounding.

It has not certified these peptides as safe, effective, or FDA-approved medicines,” he adds.

Toufiq Rashid is a journalist with over 25 years of experience in print and digital media.

She covers health and lifestyle.

Peptides referenced: Semaglutide, Tirzepatide, Liraglutide, GLP-1.

Vendors referenced: In Peptides.